Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.22.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenues        
Services $ 10,046 $ 0 $ 70,300 $ 0
Product 29,706 24,782 83,663 50,312
Total Revenues 39,752 24,782 153,963 50,312
Operating Expenses        
Research and development 3,279,323 2,935,720 6,869,376 7,522,547
General and administrative 3,085,840 2,427,806 5,687,992 3,626,759
Sales and marketing 1,774,064 561,913 3,373,047 886,772
Total Operating Expenses 8,139,227 5,925,439 15,930,415 12,036,078
Operating Loss (8,099,475) (5,900,657) (15,776,452) (11,985,766)
Other Income (Expenses)        
Grant income 393,440 391,532 393,440 391,532
Loss on disposal of fixed assets 0 (26,166) 0 (26,167)
Interest income 11,161 492 11,163 2,213
Interest expense (37,129) (39,688) (78,161) (81,869)
Total Other Income 367,472 326,170 326,442 285,709
Net Loss (7,732,003) (5,574,487) (15,450,010) (11,700,057)
Net Loss attributable to Non-Controlling Interest 82,302 47,539 166,279 56,963
Net Loss attributable to VolitionRx Limited Stockholders (7,649,701) (5,526,948) (15,283,731) (11,643,094)
Other Comprehensive Income / (Loss)        
Foreign currency translation adjustments 214,097 (44,548) 96,193 89,585
Net Comprehensive Loss $ (7,517,906) $ (5,619,035) $ (15,353,817) $ (11,610,472)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited $ (0.14) $ (0.10) $ (0.28) $ (0.22)
Weighted Average Shares Outstanding        
- Basic and Diluted 53,810,500 52,947,173 53,803,076 51,943,534